We were proud celebrate Eli Lilly’s plans for a $6 billion manufacturing plant in Huntsville, the largest investment in Alabama history. This enormous win for our state is the result of President Trump’s commitment to solving longstanding challenges that his predecessors allowed to languish—and his willingness to use unconventional tactics to bring key players to the negotiating table.
In the case of prescription drug prices, President Trump’s art-of-the-deal approach included an executive order that would set drug prices in the U.S. based on lower prices paid in other countries. The ensuing negotiations have ended with price concessions as well as new investments in the U.S., including the Eli Lilly plant in Huntsville.
While President Trump has gotten results using his transactional approach, it would be a mistake to codify his Most Favored Nation proposal through congressional action. Government price controls would undermine the U.S. biotech manufacturing sector that President Trump is just starting to build in Alabama and beyond.
While other countries have been all too willing to freeload off American innovation, the answer is not to import their socialized medicine schemes. All the countries laid out in the Most Favored Nation proposal control costs through some version of measurements like the quality-adjusted-life-year, which devalues patients with disabilities as less worthy of healthcare investment.
Importing their practices and prices won’t force other countries to pay their fair share. It will just cripple American’s biotech sector and make us less competitive in a world that is already seeing China rapidly gaining ground on clinical trial activity and patents for medical innovation. Maintaining our global leadership is vital to our national security.
The Trump Administration must and will continue to use its deal-making skills to bring other nations to the table to pay their fair share. Meanwhile, Congress should focus on reforms that unleash our free market, reduce unnecessary regulatory burdens and protect intellectual property rights, encouraging competition and innovation. These policies will lower drug costs over time while expanding patient choice and preserving incentives for lifesaving medical breakthroughs.
Alabama now has a critical stake in the outcome of this debate. As we stand ready to reap the benefits from Eli Lilly’s arrival to the state, we urge our delegation to oppose codifying Most Favored Nation and to support the free-market principles that made the U.S. the world’s leader in innovation.
